TY - JOUR A1 - Jain, Devendra A1 - Kumar, Pradeep A1 - Chowdhuri, Sanjib A1 - Doshi, Hitesh A1 - Jain, Umesh A1 - Beergouder, Savitha A1 - Maganti, Krishnasree A1 - Rani, Rashmi A1 - Mohod, Bhagyashree A1 - Jaiswal, Ashok T1 - A retrospective analysis of real-world data to evaluate the safety and effectiveness of topical amorolfine in tinea infection Y1 - 2022/7/1 JF - Indian Journal of Drugs in Dermatology JO - Indian J Drugs Dermatol SP - 66 EP - 72 VL - 8 IS - 2 UR - https://www.ijdd.in/article.asp?issn=2455-3972;year=2022;volume=8;issue=2;spage=66;epage=72;aulast=Jain DO - 10.4103/ijdd.ijdd_8_22 N2 - Background: Conventional antifungals are becoming resistant against dermatophytosis due to development of recalcitrant tinea. These patients may get benefit from newer topical antifungals or combination therapy. Topical antifungal therapy is the mainstay in the treatment of dermatophytosis. Aims/Objectives: To evaluate the safety and effectiveness of topical amorolfine in tinea infection in real-world settings. Materials and Methods: This was a real-world retrospective study; data was collected from 106 centers across India on the usage of amorolfine in the management of tinea infections. The treatment response was evaluated at the end of 2 and 4 week. It was determined by the reduction in severity of the classic symptoms of disease viz. pruritus, burning sensation, erythema, and scaling and crusting at Week 2 and Week 4 of treatment. The severity of symptoms was classified and quantified as mild (1), moderate (2), and severe (3). Safety was determined based on the occurrence of any adverse events during the treatment. Results: An improvement in symptoms score was observed for all the classic symptoms of infection viz. pruritus, burning sensation, erythema, and scaling and crusting at Week 2 and Week 4 compared to baseline. Mean total symptom score (TSS) was reduced to 0.88 ± 1.19 from 7.18 ± 2.84 at week 4 (P < 0.05). Only 10 (0.73%) patients out of 1358 showed mild and non-treatment-related adverse events. Conclusion: Amorolfine alone or in combination therapy with oral antifungals in real world clinical setting represents an improved treatment strategy for patients with tinea infections. ER -